Trial Puts Routine Opioid Prescriptions for Hysterectomy to the Test

A randomized trial published in Obstetrics & Gynecology is challenging a routine part of post-surgical care: the automatic opioid prescription after minimally invasive hysterectomy. Researchers found that patients managed with acetaminophen and ibuprofen alone reported pain levels comparable to those given the same drugs plus oxycodone, meeting statistical criteria for noninferiority.

The study, led by Mostafa Borahay, MD, PhD, of Johns Hopkins University, tracked 64 adults who underwent laparoscopic or robotic hysterectomy for benign conditions at an academic medical center between January 2023 and January 2024. On the 11-point Numeric Rating Scale, mean pain scores were 4.0 for the non-opioid group versus 5.0 for the opioid group on postoperative day 1, and 2.1 versus 3.1 on day 7 — within the bounds required to show that the non-opioid approach was not inferior.

Patient satisfaction was similar in both arms: 91% of the non-opioid group and 90% of the opioid group reported being satisfied with their pain control on day 1, and by day 7 satisfaction reached 100% in both groups. Patients in the non-opioid arm could request an opioid rescue prescription if needed; eight of the 31 did so, and none asked for a second one. In the opioid arm, patients received 12 tablets of 5-mg oxycodone, but the median consumption by day 7 was just one tablet.

The findings matter beyond the operating room. With more than 330,000 minimally invasive hysterectomies performed each year in the United States and up to 6.8% of patients at risk of persistent opioid use after the procedure, the authors argue that routine opioid prescribing contributes to oversupply at a time when leftover medications feed a wider epidemic. Borahay said the practice may be a carryover from the era of open surgery that needs robust reassessment.

Advertisement

What the Trial Data Say About Opioid Prescribing After Hysterectomy

Why One Tablet Versus Twelve Matters

The gap between what is prescribed and what is actually consumed is the story's most striking detail. Opioid-arm patients received 12 oxycodone tablets, yet the median use by day 7 was a single tablet, and just three patients in that group requested a second prescription. In the non-opioid arm, roughly a quarter of patients (8 of 31) asked for opioids at some point, but none needed a refill. That pattern suggests a standard 12-tablet prescription is poorly matched to typical needs — and that a substantial share of patients can be managed without any opioid exposure at all.

The Overprescription Pipeline

The study connects routine prescribing to the broader opioid problem through simple arithmetic: hundreds of thousands of hysterectomies each year, each potentially generating leftover pills. With up to 6.8% of hysterectomy patients at risk of persistent opioid use, the authors argue that even a small reduction in routine exposure could have measurable public-health consequences. The point is not that opioids are never appropriate — the data show some patients needed them — but that an individualized, multimodal-first approach could replace blanket prescribing.

Caveats That Should Temper Enthusiasm

This is a small, single-center, unblinded trial, and the authors acknowledge several limitations. Pain management in the post-anesthesia care unit was not standardized, opioid consumption was self-reported, and patients with chronic pain — a known predictor of postoperative opioid use — were excluded, which may have made total consumption look lower than it would be in the wider patient population. Those factors mean the results support, rather than settle, the case for non-opioid-first protocols.

The Path From Evidence to Protocol

Borahay's argument is that postoperative opioid prescribing is inherited from open-surgery practice and deserves rigorous re-testing in the minimally invasive era. The practical question for hospitals is whether enhanced recovery pathways should make non-opioid regimens the default, with opioids available as a rescue option for the minority of patients who need them. Larger, blinded, multi-center studies would give surgical teams the confidence to codify that change.

What Surgical Teams and Patients Should Take From the Trial

For Gynecologic Surgery Teams and Hospitals

  • Consider a non-opioid-first default for minimally invasive hysterectomy: in this trial, acetaminophen 500 mg and ibuprofen 600 mg alone produced satisfaction above 90% on day 1 and 100% by day 7 — while 8 of 31 patients still requested opioid rescue, so keep a prompt escalation pathway in place.
  • Right-size opioid prescriptions when they are used: the opioid arm's median consumption was one of 12 oxycodone tablets, suggesting smaller dispensed quantities would cover typical needs and reduce leftover pills.
  • Weigh the population-level exposure: with roughly 330,000 minimally invasive hysterectomies performed annually and up to 6.8% of patients at risk of persistent opioid use, reducing routine prescribing could shrink the pool of unused opioids.

For Patients Scheduled for Hysterectomy

  • Ask your surgical team before the operation whether a non-opioid pain plan with an opioid rescue option is appropriate for your case — and disclose any chronic pain history, since this trial excluded those patients and their needs may differ.